LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

28.61 -1.99

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.42

Max

29.3

Belangrijke statistieken
By Trading Economics
Inkomsten	43M 13M
Verkoop	29M 107M
EPS	0.25
Winstmarge	12.139
Werknemers	524
EBITDA	16M 8.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+112.73% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	18M 1.5B
Vorige openingsprijs	30.6
Vorige sluitingsprijs	28.61

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2026, 22:54 UTC

Winsten

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mei 2026, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 mei 2026, 23:51 UTC

Marktinformatie

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mei 2026, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 mei 2026, 23:17 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mei 2026, 23:16 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mei 2026, 23:15 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mei 2026, 23:14 UTC

Winsten

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mei 2026, 23:02 UTC

Marktinformatie

Winsten

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mei 2026, 22:59 UTC

Marktinformatie

Winsten

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mei 2026, 22:24 UTC

Winsten

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mei 2026, 22:23 UTC

Winsten

Xero FY International Revenue Growth 47%>XRO.AU

13 mei 2026, 22:22 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mei 2026, 22:19 UTC

Winsten

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mei 2026, 22:18 UTC

Winsten

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mei 2026, 22:16 UTC

Winsten

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mei 2026, 22:15 UTC

Winsten

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mei 2026, 22:13 UTC

Winsten

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mei 2026, 22:12 UTC

Winsten

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mei 2026, 22:11 UTC

Winsten

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

13 mei 2026, 22:10 UTC

Winsten

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mei 2026, 22:09 UTC

Winsten

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mei 2026, 22:00 UTC

Winsten

Cisco to Shed Jobs for All-In AI Push -- Update

13 mei 2026, 21:11 UTC

Winsten

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

112.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 112.73%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.